Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

By Reuters News

- French drugmaker Sanofi SASY.PA said on Thursday it would pay US partner Regeneron REGN.O $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.

The companies said they had settled earlier litigation over the collaboration and that they would split costs and profits of the expanded partnership equally.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk